Bank of America Corp DE Sells 84,485 Shares of Replimune Group, Inc. (NASDAQ:REPL)

Bank of America Corp DE cut its position in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 77.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 24,423 shares of the company's stock after selling 84,485 shares during the quarter. Bank of America Corp DE's holdings in Replimune Group were worth $296,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Boxer Capital Management LLC purchased a new position in shares of Replimune Group in the 4th quarter worth about $21,754,000. Price T Rowe Associates Inc. MD raised its position in Replimune Group by 11.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,962,883 shares of the company's stock worth $132,761,000 after acquiring an additional 1,083,633 shares during the period. Marshall Wace LLP purchased a new position in Replimune Group in the fourth quarter valued at about $10,853,000. Wellington Management Group LLP grew its position in shares of Replimune Group by 352.5% during the 4th quarter. Wellington Management Group LLP now owns 1,096,744 shares of the company's stock valued at $13,282,000 after acquiring an additional 854,346 shares during the period. Finally, Artisan Partners Limited Partnership bought a new position in shares of Replimune Group during the 4th quarter valued at approximately $7,399,000. 92.53% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

REPL has been the topic of a number of research reports. JPMorgan Chase & Co. lifted their price target on shares of Replimune Group from $16.00 to $18.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. Piper Sandler boosted their target price on Replimune Group from $14.00 to $22.00 and gave the company an "overweight" rating in a research note on Monday, June 2nd. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $20.83.

Replimune Group Stock Performance

Shares of NASDAQ REPL traded down $0.32 during midday trading on Tuesday, hitting $9.51. The company's stock had a trading volume of 859,781 shares, compared to its average volume of 892,020. The firm has a market capitalization of $733.13 million, a price-to-earnings ratio of -3.10 and a beta of 0.63. The company has a current ratio of 7.95, a quick ratio of 7.95 and a debt-to-equity ratio of 0.17. The stock has a fifty day moving average price of $8.70 and a 200 day moving average price of $10.85. Replimune Group, Inc. has a one year low of $6.44 and a one year high of $17.00.

Replimune Group (NASDAQ:REPL - Get Free Report) last announced its quarterly earnings results on Thursday, May 22nd. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same quarter in the prior year, the firm posted ($0.25) earnings per share. On average, research analysts forecast that Replimune Group, Inc. will post -2.97 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Christopher Sarchi sold 3,749 shares of the business's stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $8.05, for a total transaction of $30,179.45. Following the completion of the transaction, the insider now directly owns 128,296 shares in the company, valued at $1,032,782.80. The trade was a 2.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Andrew Schwendenman sold 3,287 shares of Replimune Group stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $8.05, for a total value of $26,460.35. Following the sale, the chief accounting officer now directly owns 68,284 shares of the company's stock, valued at $549,686.20. This represents a 4.59% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 74,907 shares of company stock worth $603,655 in the last quarter. 8.80% of the stock is owned by company insiders.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.